Stock Watch: Sanofi’s Vaccine Gap-Filling Aspirations

Exceeding €10bn In Vaccine Sales By 2030 Might Be A Stretch

Phase II studies of vaccines involve more variables than for drugs and these can be compounded by seasonality. This can make the time until vaccine approval longer than would be expected for drugs.

Stock Watch Image, Andy Smith
ANDY SMITH OFFERS A LIFE SCIENCE INVESTOR'S PERSPECTIVE ON BIOPHARMA BUSINESS

More from Stock Watch

More from Business